CMS resolves hypoglossal nerve stimulation reimbursement confusion by adding 6 new HCPCS codes (effective Jan 1, 2026), viewed as positive for Inspire & Nyxoah.
Inspire Medical shares dropped after Medicare corrected a reimbursement error, prompting Oppenheimer to downgrade the stock while Evercore remained optimistic.
Inspire Medical shares fall after Medicare billing code confusion, but major analysts remain confident in long-term growth.
Morgan Stanley updates ratings for Inspire Medical, DexCom, and Bausch + Lomb, highlighting slowing growth, improving operations, and strong long-term pipelines.
Inspire Medical Systems stock jumps after CMS approves major Medicare payment increase for sleep apnea procedures, effective 2026. Stifel upgrades to Buy.
